-
Sanofi Acquires Rare Disease Candidate INBRX-101 in $1.7 Billion Deal
•
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced the acquisition of INBRX-101, a promising candidate for rare genetic diseases, from U.S. biotechnology firm Inhibrx (NASDAQ: INBX). INBRX-101, currently in Phase II trials for alpha-1 antitrypsin deficiency (AATD), is a recombinant human AAT-Fc fusion protein designed to restore serum AAT activity,…
